Juno Bio Vaginal Microbiome Test

The current offer has a confirmed $149 one-off price and a $99 recurring price per test every three months, with results, coaching, and the stated STI screen included where available. Refund rules are explicit, but cancellation requires two payments, prescriptions and pharmacy costs are separate, international return postage is customer-paid, and the reviewed sources do not provide an independent value comparison for this specific assay.

The offer states that it screens more than 10,000 bacteria and fungi and names representative organisms, with four STI targets in 46 US states. That is useful breadth for a vaginal microbiome question. The complete analyte list, target-level inclusion and exclusion rules, analytical coverage, and the relationship between broad NGS detection and the separate STI screen remain undisclosed.

The declared question is directly aligned with the product's vaginal microbiome composition scope, and Juno gives explicit wellness, clinical-support, and state-specific boundaries. The report offers context and physician sharing, but public evidence does not establish how detected organisms, relative abundance, or the STI screen map to individual diagnoses or treatment decisions. Clinical relevance is therefore useful but bounded.

The sample report shows a secure dashboard, microbiome type, quantitative load, positive-microbe breakdown, categories, scientific context, downloadable and shareable results, coaching, and physician next steps. It does not expose report thresholds, uncertainty, quality flags, reference ranges, or target-specific clinical validity. The provider's legal limits reduce the risk of a diagnostic reading but also limit direct actionability.

Juno identifies NGS, extraction, quality screening, a proprietary bioinformatic pipeline, curated databases, and licensed review. It also states a CLIA high-complexity laboratory, but the published CLIA number returned no active match in the CMS lookup, while exact assay design, validation tables, and numeric performance data were not found. The method is materially described, yet the credential conflict prevents a higher score without treating the assay as invalid.

US ordering and collection are practical and well described: online purchase, home lower-vaginal swab, prepaid return, no referral, dashboard release, coaching, and a stated 4-9 business day result window from sample receipt. International customers arrange their own return postage, STI screening is excluded in four states and internationally, and physician or prescription services depend on eligibility.

Juno provides a substantial privacy record covering sensitive health and sex-life data, sample processing, research, retention until opt-out or deletion, security measures, disclosure categories, and privacy requests. The record does not give fixed sample destruction or result-retention periods, the terms grant broad data rights for research and AI improvement, and the no-sale product statement needs reconciliation with targeted-advertising sharing and state-law opt-out language.

Juno discloses the core offer, home-swab route, NGS method family, price options, result access, terms, privacy pages, and explicit non-diagnostic limitations. However, the exact published CLIA number has no active CMS match, the current product page contains a 3-versus-4 STI inconsistency, and turnaround language varies between 4-9 business days and 5-10 working days. These are material audit and buyer-decision gaps.